S
Sibylla Biotech
Facing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs
About Sibylla Biotech
Sibylla Biotech is a preclinical stage company that focuses on developing innovative small molecule degraders to address unmet medical needs. Utilizing a novel Mechanism of Action called Protein Inactivation by Folding Intermediates (PPI FIT), Sibylla identifies and develops small molecules that target proteins involved in various diseases. The company operates in the biopharmaceutical market and collaborates with academic institutions like the Italian National Institute of Nuclear Physics, the University of Trento, and the University of Perugia. Sibylla's business model revolves around drug discovery and development, leveraging advanced computational simulations and AI platforms to accelerate the identification of potential therapeutics. Revenue is generated through partnerships, grants, and potential future licensing deals. The company serves pharmaceutical companies and research institutions looking for novel therapeutic solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Bresso, Italy
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 78.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, Biotech and Pharma
- Technology
- Artificial Intelligence, Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2022 | $25M | $101M | CDP Venture Capital · Seroba Life Sciences · 3B Future Health Fund · Vertis | ↗ |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | University of Trento · Italian Institute for Nuclear Physics · University of Perugia | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Sibylla Biotech is 1K monthly website visits, up 78.6% over the last three months. Sibylla Biotech's team grew 13.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
V-Bio Ventures
CDP Venture Capital
Seroba Life Sciences
3B Future Health Fund
Vertis
VI Partners
Indaco Venture Partners
Claris Ventures
Other known investors4 additional known investors
Italian Institute for Nuclear Physics
University of Perugia
University of Trento
Obloo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sibylla Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sibylla Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.